DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 020364/S-048 **SUPPLEMENT APPROVAL**

Novartis Pharmaceuticals Corporation
Attention: Andrew Kucerovy
Regulatory CMC Manager, Global Regulatory CMC
One Health Plaza
East Hanover, NJ 07936-1080

Dear Dr. Kucerovy:

Please refer to your supplemental new drug application dated July 31, 2009, received July 31, 2009, submitted under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Amlodipine besylate/Benazepril hydrochloride 2.5/10 mg, 5/10 mg, and 10/20 mg Capsules.

This "Prior Approval Supplement" supplemental new drug application provides for changes to the **HOW SUPPLIED**, **CONTRAINDICATIONS** and **PRECAUTIONS** sections of the label as well as the addition of a blister pack configuration; the addition of the Novartis, Suffern, New York facility; (b) (4) for the blister packaging; the addition of two new contract packaging facilities for (b) (4) as a Quality Control and Stability testing site for (b) (4), and the inclusion of art work for the new blister pack labels and the corresponding shellpak labels. The following changes to the label have been made:

1. In **CONTRAINDICATIONS**, the first paragraph has been changed from:

   Amlodipine besylate and benazapril hydrochloride combination capsules is contraindicated in patients who are hypersensitive to benazepril, to any other ACE inhibitor, or to amlodipine.

   To:

   Amlodipine besylate and benazapril hydrochloride combination capsules are contraindicated in patients with a history of angioedema, with or without previous ACE inhibitor treatment, or patients who are hypersensitive to benazepril, to any other ACE inhibitor, or to amlodipine.

2. In **PRECAUTIONS/Drug Interactions**, the following has been added to the list of interactions:

Gold: Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy.

3. In **HOW SUPPLIED**, the last sentence of the paragraph has been changed from:

   All four strengths are packaged as follows:

   To:

   All four strengths are packaged in bottles or blisters as follows:

4. In **HOW SUPPLIED**, the NDC numbers have been added for the blister packs. The table now reads:

Dose	Capsule Color/Code	NDC Code Bottle of 100	NDC Code Bottle of 1000	NDC Code Unit dose carton of 30 (1 x 30 capsule blister cards)
2.5/10 mg	white with 2 gold bands/571	NDC 0781-2271-01	-	NDC 0781-2271-64
5/10 mg	light brown with 2 white bands/572	NDC 0781-2272-01	NDC 0781-2272-10	NDC 0781-2272-64
5/20 mg	pink with 2 white bands/573	NDC 0781-2273-01	NDC 0781-2273-10	NDC 0781-2273-64
10/20 mg	purple with 2 white bands/574	NDC 0781-2274-01	NDC 0781-2274-10	NDC 0781-2274-64

5. The revision date and version number have been updated.

We have completed our review of this application, and it is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed upon labeling text, which is identical to the content of labeling [21 CFR 314.50(l)(1)(i)] in structured product labeling (SPL) format submitted on July31, 2009.

Submit final printed carton and container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (October 2005)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission "**Final Printed Carton and Container Labels for approved NDA 20364/S-048**." Approval of this submission by FDA is not required before the labeling is used.

If you have any questions, please call:

Lori Anne Wachter, RN, BSN
Regulatory Project Manager
(301) 796-3975

Sincerely,

{See appended electronic signature page}

Mary Ross Southworth, Pharm. D.
Deputy Director for Safety
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure:
Content of Labeling

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
NDA-20364	SUPPL-48	NOVARTIS PHARMACEUTICALS CORP	LOTREL (AMLODIPIDINE/BENAZEPRIL)CAPSULES

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARY R SOUTHWORTH
12/22/2009